Lantheus Holdings, Inc.
LNTHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. At a $7.00B market cap, Lantheus Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Market Cap
$7.00B
Beta
-0.06
P/E (TTM)
25.08
P/E (Fwd)
16.95
EPS (TTM)
$4.29
EPS (Fwd)
$6.35
ROE
23.5%
ROA
8.2%
Cash
$498.6M
Total Debt
$625.8M
Free CF
$421.7M
52W Change
53.3%
Annual Financials
Cash vs Debt
Lantheus Holdings, Inc. carries $625.8M in total debt against $498.6M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $421.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 23.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $425.2M (2021) to $1.54B (2025), reflecting a 263% increase over the period.
The relatively low beta of -0.06 suggests LNTH is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing LNTH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.